Evidence map›Paper›PMID 42882486›Full record

ArticleCells2026

Homoharringtonine Suppresses Prostate Cancer Progression Through Modulation of the TNF/NF-κB and MAPK Signaling Pathways.

Yuzhong Chen, Sisi Huang, Dongyan Huang, Yangtao Jin, Congcong Shao, Xin Su, Rongfu Yang, Juan Jiang, Jianhui Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuzhong ChenNHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School of Pharmaceutical Sciences Fudan University, Shanghai 200237, China.
Sisi HuangNHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School of Pharmaceutical Sciences Fudan University, Shanghai 200237, China.ORCID 0000-0003-0452-4461
Dongyan HuangNHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School of Pharmaceutical Sciences Fudan University, Shanghai 200237, China.
Yangtao JinNHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School of Pharmaceutical Sciences Fudan University, Shanghai 200237, China.
Congcong ShaoNHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School of Pharmaceutical Sciences Fudan University, Shanghai 200237, China.
Xin SuNHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School of Pharmaceutical Sciences Fudan University, Shanghai 200237, China.
Rongfu YangNHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School of Pharmaceutical Sciences Fudan University, Shanghai 200237, China.
Juan JiangNHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School of Pharmaceutical Sciences Fudan University, Shanghai 200237, China.
Jianhui WuNHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School of Pharmaceutical Sciences Fudan University, Shanghai 200237, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) represents one of the leading causes of cancer-related mortality among men. The efficacy of its treatment is often compromised by chemotherapeutic toxicity and multidrug resistance, underscoring the urgent need to develop efficient and low-toxicity alternative therapeutic strategies. Homoharringtonine (HHT), a bioactive compound, has demonstrated clinical anticancer efficacy in hematologic malignancies. However, its role and underlying mechanisms in prostate cancer remain largely unclear. This study provides evidence that HHT suppresses prostate cancer cell proliferation and promotes cell cycle arrest by modulating the TNF/NF-κB and MAPK signaling pathways, indicating its potential as a promising natural drug candidate for PCa treatment.

Indexed as

Disease ProgressionHomoharringtonineMAP Kinase Signaling SystemNF-kappa BProstatic NeoplasmsTumor Necrosis Factor-alphaCell Cycle CheckpointsCell Line, TumorCell ProliferationHumansMaleHomoharringtonineNF-kappa BTumor Necrosis Factor-alphahomoharringtoninenatural productprostate cancer

Identifiers

PMID42882486
PMCPMC13664184

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.